Evolving Dynamics In Biopharma: Market Trends, AI Integration In Drug Discovery, And The Regulatory Landscape Of Biologics And CDMOs

The demand for drug discovery, biologics, and gene therapy has surged, with monoclonal antibodies leading biologics growth. AI and mRNA vaccines gained prominence, while cancer treatments remain the top focus in R&D. The pipeline is dominated by small molecules, followed by biologics, and gene therapy remains limited. The industry faces challenges in clinical trials, where patient recruitment and manufacturing scale-up pose risks. AI is advancing drug design, but its impact on clinical trials and large-scale drug discovery is still developing.